Pfizer is facing patent cliffs on multiple drugs in the next few years. The company has been making big acquisitions to ...
Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have yielded a 7 ...
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Pfizer is getting out of the business of developing and marketing HIV medicines by exiting its minority stake in ViiV Healthcare, a company the pharmaceutical giant formed in partnership with GSK 17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results